Ascendia Pharmaceuticals

Article

Sponsored Content

Ascendia is a speciality CDMO dedicated to developing enhanced formulations for poorly water-soluble molecules. Ascendia provides comprehensive services-analytical, preformulation, formulation development, and cGMP manufacture of clinical materials. Ascendia formulates products for injection, topical delivery, and for oral administration. Our formulation expertise includes nanoparticles, nano-emulsions, and amorphous solid dispersions.

Ascendia Pharmaceuticals
675 US Highway One, North Brunswick, NJ 08902
tel. 732.640.0058
INTERPHEX Booth #1567

Recent Videos
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Related Content
Question mark background | Image Credit: © Leigh-Prather - © Leigh Prather - stock.adobe.com

Complying with European versus US GMPs

Siegfried Schmitt
May 2nd 2025
Article

While global harmonization exists, there are still differences between the US and European GMP requirements that manufacturers should know, says Siegfried Schmitt, PhD, vice president, Technical at Parexel.

Site Logo

Transformations in Drug Development for Cell and Gene Therapies

PPD;Thermo Fisher Scientific
March 28th 2025
Podcast

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.

High Angle Shot of a Working Desk of an Successful Person in Office with Cityscape Window View. | Image credit: © Gorodenkoff - stock.adobe.com

Quality, Resilience, and Reinvention in Pharma Manufacturing

Mike Hennessy Jr.
May 1st 2025
Article

The pharma industry is focused on strengthening its foundation, embracing innovation, and future-proofing its path forward.

Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang

Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang

PPD;Thermo Fisher Scientific
March 28th 2025
Podcast

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Capsida Previews Its Oral and Poster Presentations for ASGCT 2025

Patrick Lavery
April 29th 2025
Article

The company’s exhibitions will be focused in the areas of its pipeline, proprietary capsid engineering, and manufacturing.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

CHMP Recommends argenx Treatment for Chronic Inflammatory Demyelinating Polyneuropathy

Patrick Lavery
April 28th 2025
Article

The company said that Vyvgart (efgartigimod alfa) is the first novel mechanism of action for CIDP treatment in more than 30 years.